Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Mimedx (MDXG) Gross Margin (2016 - 2025)

Historic Gross Margin for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to 83.54%.

  • Mimedx's Gross Margin rose 17700.0% to 83.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 81.99%, marking a year-over-year decrease of 13800.0%. This contributed to the annual value of 82.78% for FY2024, which is 2200.0% down from last year.
  • Per Mimedx's latest filing, its Gross Margin stood at 83.54% for Q3 2025, which was up 17700.0% from 81.05% recorded in Q2 2025.
  • Over the past 5 years, Mimedx's Gross Margin peaked at 86.03% during Q4 2021, and registered a low of 80.68% during Q4 2022.
  • For the 5-year period, Mimedx's Gross Margin averaged around 82.75%, with its median value being 82.67% (2023).
  • Its Gross Margin has fluctuated over the past 5 years, first crashed by -53500bps in 2022, then skyrocketed by 33800bps in 2023.
  • Quarter analysis of 5 years shows Mimedx's Gross Margin stood at 86.03% in 2021, then dropped by -6bps to 80.68% in 2022, then increased by 4bps to 84.06% in 2023, then fell by -3bps to 81.8% in 2024, then grew by 2bps to 83.54% in 2025.
  • Its Gross Margin stands at 83.54% for Q3 2025, versus 81.05% for Q2 2025 and 81.23% for Q1 2025.